Kaken Pharmaceutical Co., Ltd.
KKPCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $94,035 | $72,044 | $72,984 | $76,034 |
| % Growth | 30.5% | -1.3% | -4% | – |
| Cost of Goods Sold | $35,502 | $33,505 | $33,428 | $34,458 |
| Gross Profit | $58,532 | $38,539 | $39,556 | $41,576 |
| % Margin | 62.2% | 53.5% | 54.2% | 54.7% |
| R&D Expenses | $18,725 | $12,543 | $15,789 | $8,420 |
| G&A Expenses | $0 | $31 | $0 | $0 |
| SG&A Expenses | $18,501 | $16,165 | $15,476 | $15,833 |
| Sales & Mktg Exp. | $0 | $16,134 | $0 | $0 |
| Other Operating Expenses | $273 | $318 | $334 | $130 |
| Operating Expenses | $37,499 | $29,026 | $31,553 | $24,508 |
| Operating Income | $21,034 | $9,513 | $7,998 | $17,064 |
| % Margin | 22.4% | 13.2% | 11% | 22.4% |
| Other Income/Exp. Net | -$1,599 | $283 | -$1,181 | -$3,179 |
| Pre-Tax Income | $19,435 | $9,796 | $6,817 | $13,885 |
| Tax Expense | $5,490 | $1,770 | $1,377 | $4,336 |
| Net Income | $13,945 | $8,025 | $5,440 | $9,549 |
| % Margin | 14.8% | 11.1% | 7.5% | 12.6% |
| EPS | 365.42 | 212.66 | 144.79 | 251.44 |
| % Growth | 71.8% | 46.9% | -42.4% | – |
| EPS Diluted | 365.42 | 212.66 | 144.79 | 251.44 |
| Weighted Avg Shares Out | 38 | 38 | 38 | 38 |
| Weighted Avg Shares Out Dil | 38 | 38 | 38 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $77 | $8 | $7 | $6 |
| Interest Expense | $28 | $17 | $17 | $17 |
| Depreciation & Amortization | $2,554 | $2,753 | $2,568 | $2,481 |
| EBITDA | $22,017 | $12,566 | $9,402 | $16,384 |
| % Margin | 23.4% | 17.4% | 12.9% | 21.5% |